RET and non-small cell lung carcinoma: LOXO-NGR-21001 is a global phase I study of LOXO-260 in patients with RET-altered solid tumors (including RET fusion + NSCLC) that must have received a prior RET inhibitor closed at the enrollment; we are awaiting the results [103].